Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Kalydeco“
Suchtreffer
Begriffe & Kennungen
Kalydeco · 4.8 · During the 24-week, open-label phase 3 study in patients aged 6 to less than 12 years (study 661-113 part B, n
Eintrag öffnenKalydeco · 4.8 · During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were
Eintrag öffnenKalydeco · 4.8 · During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were
Eintrag öffnenKalydeco · 4.8 · During the 48-week placebo-controlled studies 770-102 and 770-103 in patients aged 6 years and older, the inci
Eintrag öffnenKalydeco · 4.8 · During the 48-week placebo-controlled studies 770-102 and 770-103 of ivacaftor as monotherapy in patients aged
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper
Eintrag öffnenKalydeco · 4.8 · In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of maximum creatine phosphokinase > 5 x the ULN was 10.4% in ivacaftor/tezacaf
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of maximum creatine phosphokinase > 5 x the ULN was 10.4% in ivacaftor/tezacaf
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in ivacaftor/tezacaftor/e
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in ivacaftor/tezacaftor/e
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the maximum increase from baseline in mean systolic and diastolic blood pressure was 3.5 mmH
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the maximum increase from baseline in mean systolic and diastolic blood pressure was 3.5 mmH
Eintrag öffnenKalydeco · 4.8 · In study 770-108 ivacaftor was permanently discontinued in one patient. In study 770-124, in the cohort of pat
Eintrag öffnenKalydeco · 4.8 · In study 770-108 ivacaftor was permanently discontinued in one patient. In study 770-124, in the cohort of pat
Eintrag öffnenKalydeco · 4.8 · Increased blood pressure
Eintrag öffnenKalydeco · 4.8 · Increased blood pressure
Eintrag öffnenKalydeco · 4.8 · Increased creatine phosphokinase
Eintrag öffnen